Yoon BK, et al. - The therapeutic potential of menopausal hormone therapy (MHT) was investigated in women with mild cognitive impairment (MCI). Researchers randomly assigned 37 postmenopausal women (age range: 57-82 y) with multiple-domain, amnestic subtype MCI to either placebo (n = 18) or MHT (n = 19) for 24 months (percutaneous estradiol [E2] gel [0.1%, 2 mg/d] and oral micronized progesterone [MP4] [100 mg/d]). Outcomes suggest that cognitive decline in postmenopausal women with MCI could be reduced using long-term MHT including percutaneous E2 gel and oral MP4.